Clinical Trial Update: Replicor Compassionate Access Program

View source ↗

Summary

Replicor's compassionate access program for hepatitis B and hepatitis D, along with related liver diseases, is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ascites
• Decompensated Cirrhosis
• Esophageal Varices
• Hepatitis B
• Hepatitis D
• Hepatocellular Carcinoma
• Liver Cirrhosis

Drugs mentioned

• REP 2139 (nucleic acid polymer)

Snippet

Sponsor: Replicor Inc. | Conditions: Viral Hepatitis B, Viral Hepatitis D | Status: NO_LONGER_AVAILABLE